Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
01:37am, Thursday, 13'th Aug 2020
REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to
Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock
08:01pm, Tuesday, 11'th Aug 2020
REDWOOD CITY, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to
Adverum Biotechnologies, Inc. (ADVM) Q2 2020 Earnings Call Transcript
05:30pm, Tuesday, 11'th Aug 2020
ADVM earnings call for the period ending June 30, 2020.
Adverum Biotechnologies (ADVM) Gets a Buy Rating from Leerink Partners - Markets
12:33pm, Tuesday, 11'th Aug 2020
In a report released today, Mani Foroohar from Leerink Partners maintained a Buy rating on Adverum Biotechnologies (ADVM – Research
BidaskClub Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold
10:50am, Tuesday, 11'th Aug 2020
BidaskClub lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a hold rating in a research note released on Saturday morning, BidAskClub reports. Several other brokerages ha
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Sees Large Drop in Short Interest
01:34am, Tuesday, 11'th Aug 2020
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,990,000 shares, a decrease of 6.1% from t
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates
09:35pm, Monday, 10'th Aug 2020
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the sto
\-- Continued robust treatment response from both high and low doses -- \-- Long-term durability beyond 15 months from single IVT injection with zero rescue injections in Cohort 1 --\-- Well tolerate
Regeneron’s Covid-19 Treatment Could Be as Big a Deal as a Vaccine
06:11pm, Monday, 10'th Aug 2020
Biotech Regeneron Pharmaceuticals has a cocktail of antibodies for treating Covid-19. Cannacord analyst John Newman says the treatment is “critical” because a vaccine can’t treat an active disea
Sutro Biopharma (NASDAQ:STRO) and Adverum Biotechnologies (NASDAQ:ADVM) Head-To-Head Contrast
10:04pm, Sunday, 09'th Aug 2020
Sutro Biopharma (NASDAQ:STRO) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strengt
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
12:00am, Friday, 07'th Aug 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
The Dow Is Up 300 Points. Here’s Why the Stock Market Is Looking Past Dismal Jobs Data.
04:55pm, Wednesday, 05'th Aug 2020
The ADP jobs report was terrible. The ISM Services survey was not. What to make of the mixed messages?
Regeneron Stock Climbs as Earnings Come in Strong
01:02pm, Wednesday, 05'th Aug 2020
The company reported double-digit growth on both the top and bottom lines. Monday, it reported promising results from an animal trial of a treatment and preventative for Covid-19.
Adverum Biotechnologies (NASDAQ:ADVM) Rating Increased to Buy at ValuEngine
07:40am, Wednesday, 05'th Aug 2020
Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Monday, ValuEngine reports. A number of other
